Molecular Detection of *bla* OXA-48 Gene Encoding Carbapenem Resistance *Pseudomonas aeruginosa* Clinical Isolates from Khartoum State Hospitals, Sudan

Doha Omer Ali and Mohamed M.A.Nagla*

Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, Al-Neelain University, Khartoum, Sudan

*Corresponding author: nag.mas@hotmail.com

Abstract

Carbapenem resistance in *Pseudomonas aeruginosa* is particularly worrisome because this class of β -lactam represents the last therapeutic resource for control of bacterial infection. So this study aimed to detect the frequency of *bla* OXA-48 resistance gene among *Pseudomonas aeruginosa* clinical isolates during the period from November 2018 to November 2019.

Hundred *Pseudomonas aeruginosa* clinical isolates, 81 carbapenems (imipenem meropenem) resistant and 19 carbapenems sensitive were collected from Omdurman Teaching Hospital, Fedail Hospital and Soba Teaching Hospital in Khartoum State-Sudan. All isolates were re-identified using conventional bacteriological techniques, their susceptibility to carbapenems were tested using Kirby-Bauer method for confirmation and investigated for the presence of the *bla* OXA-48 gene using conventional PCR technique.

60 (60.0%) out of 100 *Pseudomonas aeruginosa* clinical isolates were positive for *bla*OXA-48 gene. Out of 81 carbapenem resistant isolates 54(66.7%) were positive for *bla* OXA-48 gene, while among the (19) carbapenem sensitive isolates 6 (31.6%) were positive for *bla*OXA-48 gene. There was statistically significant association between carbapenem resistant isolates and the presence of *bla*OXA-48 gene (*P-value* = 0.006).

Wound swabs were the predominant clinical samples detected harboring *bla* OXA-48 gene both among the sensitive 5 (83.3%) and carbapenem resistant isolates 29(53.7) (*P.value*> 0.05).

Our findings revealed high frequency of *bla* OXA-48 among carbapenem resistant isolates so identification of *bla* OXA-48 producing strains and taking efforts to reduce the rate of transferring these gene between the different strains is essential for optimization of therapy and improves of patients outcomes.

Key words: *P.aeruginosa*, carbapenem resistant , *bla* OXA-48 gene, Khartoum State.

Introduction

Pseudomonas aeruginosa (*P.aeruginosa*) is gram negative bacterium.[1]. It is a lethal opportunistic pathogen that is a leading cause of morbidity and mortality in immunocompromised individuals [2]. It rarely found in the microbiota of healthy humans [3].The colonization rate by *P.aeruginosa* significantly increases (reaching up to 80%) in patients with chronic illnesses (e.g cystic fibrosis, sever burns) or extensive exposure to health care facilities involving interruption of protective barriers [4, 5]. It has an intrinsic resistance to wide range of antimicrobial agents and a high capacity to attain resistance mutations and mobile genetic elements [6]. Elimination of *P.aeruginosa* has become increasingly difficult due to its remarkable capacity to resist antibiotics [2].

Carbapenem resistance in *P.aeruginosa* is particularly worrisome because this class of β -lactam represents the last therapeutic resource for control of bacterial infection [7]. Although porins loss and efflux pumps may contribute to the phenotype of carbapenem resistance in *P.aeruginosa*, Yet the most relevant resistance mechanism is the production of carbapenem –hydrolyzing enzymes (carbapenemase)[7].

Carbapenemase producing carbapenem resistance enterobacteracea (CP- CRE) that directly break down carbapenem have been classified to various types such as class A β -lactamase (NMC, IMI, SMS, MKPC, GES), class B β -lactamase (IMP, VIM, SPM, NDM) and class D β -lactamase (OXA-48) [8]. In recent years, the emergence of diverse carbapenemase in members of the family Enterobacteriaceae has become a major challenge for health care system [9].

BlaOXA-48 gene is a class D β -lactamase that possesses the ability to hydrolyze carbapenems as well as Cloxacillin and Penicillin [10]. Studies done by Carrër , et al., (2010) indicated that the blaOXA-48 gene has been found in plasmid and located between two identical insertion sequences, IS999, forming the composite transposon Tn 1999s [11]. The genetic environment of blaOXA-48 was investigated by PCR with primers specific for insertipon sequence IS1999 and for the 5' part of blaOXA-48 [11]. Recently, Nordmann et al described a new inhibitor-based biochemical assay for carbapenemase detection [12]. But detection of OXA-48 and related enzymes remains problematic, as no specific inhibitor is available. Temocillin resistance was suggested as an indicator of OXA-48 production but not for OXA-48 confirmation [13-15].

The first case of resistance mediated by OXA-48 was identified in 2001 from multi-drug resistance *Klebsiella pneumoniae* in Istanbul Turkey [16]. Several cases of OXA-48 producing organisms like *Pseudomonas*, *E.coli* and *Cetrobacter* were reported in patients from or have relation with Turkey [17].Several isolates producing OXA-48 have been involved as a source of nosocomial outbreaks

[18, 19]. Outbreak of OXA-48 was reported worldwide, disseminating from Middle Eastern countries and North Africa. Sporadic cases have been reported in Lebanon, Oman, Saudi Arabia and Kuwait. In Africa mostly in Northern African countries of Egypt, Tunisia, Libya and Morocco [20]. And little is known about this problem in Sudan, as a rapid and reliable detection of carbapenemases is desirable in order to limit the spread of these enzymes. Thus the present study aimed to investigate the frequency of blaOXA-48 resistant gene among carbapenem resistance *P. aeruginosa*.

Materials and Methods

Design and setting

A descriptive - cross sectional study was conducted in different Khartoum State hospitals, Sudan (Omdurman Teaching Hospital, Fedail Hospital and Soba Teaching Hospital) during the period from November 2018 to November 2019. A total of 100 *Pseudomonas aeruginosa* clinical isolates of known carbapenem susceptibility from different types of clinical samples (wound swabs, urine, ear swabs, sputum and high vaginal swabs) were included in this study. They represented 81 carbapenems (imipenem meropenem) resistant and 19 carbapenems sensitive.

Pseudomonas aeruginosa clinical isolates of known resistant and sensitive to both routinely used carbapenem (Meropenem and Imipenem) antibiotics were included in this study and any clinical isolates resist or sensitive to only one carbapenem antibiotics was excluded from this study. The approval and informed consent was obtained from Faculty and Department of Medical Microbiology management, Al-Neelain University and informed consent was taken from Hospitals included in this study.

Phenotypic methods

The fresh cultured colonies of *P. aeruginosa* clinical isolates were sub-cultured on nutrient agar and macConkey agar media to ensure purity and optimal growth. Then they were re-identified using routine culture techniques and their susceptibility to carbapenems were tested using Kirby-Bauer method for confirmation.

DNA extraction

Bacterial DNA was extracted by using boiling method. All bacterial strains were sub cultured on nutrient agar and the overnight pure bacterial growth were used. Three colonies were emulsified in Eppendorf tubes containing 200µl of the distilled water and boiled at 100 °C for 30 minutes then

centrifuged at 12000 rpm for 15 minutes. The supernatant containing DNA was transferred to new Eppendorf tubes and stored at -20°C [21]

PCR amplification procedure

PCR was carried out for all isolates by using specific primer for OXA-48 gene F 5'GCGTGGTTAAGGATGAACA 3' R 5'CATCAAGTTCAACCCAACCG 3' of amplicon size of 177 bp [22]. Amplification was performed at final volume 25 µl (5µl Mater mix, 5µl from DNA, 2µl primer and 13µlD.W).The PCR cycling conditions were as follows: an initial denaturation step of 10 min at 94°C followed by 35 cycles of 30 s at 94°C, 30 s at 55°C and 30s at 72°C,with a final extension of 10 min ,(Tc-412,UK) thermo cycler machine was used.

PCR products was separated on 2% agarose gel by electrophoresis to detect specific amplified product by comparing with standard molecular weight marker 100 base pair (DNA ladder) 5µl of PCR product was loaded into the well. Electrophoresis was carried out at 100 Volts, 60 AMP and 30 minutes.

The amplified products of the study samples were visualized by Trans -illuminator. Photographed by a digital camera and transferred to computer data for labeling and storage.

Results

Hundred (100) *P.aeruginosa* clinical isolates were collected from different hospitals in Khartoum State, Sudan during the period from November 2018 to November 2019. They were obtained from different clinical samples. They represented (57) wound swabs, (24) urine, (3) ear swabs, (6) sputum and (10) high vaginal swabs (Table 1).Their identification was confirmed using conventional bacteriological techniques.

Table 1: Distribution of *Pseudomonas aeruginosa* clinical isolates according to type of specimens.

Specimens	Frequency (%)
Wound swab	57 (57.0%)
Urine	24 (24.0%)
High vaginal swab	10 (10.0%)
Sputum	6 (6.0%)
Ear swab	3 (3.0%)
Total	100 (100.0%)

Carbapenem (Meropenem and Imipenem) susceptibility testing using disc diffusion method showed that 81(81.0%) of isolates were Meropenem and Imipenem resistant, While 19 (19.0%) were Meropenem and Imipenem sensitive (Figure 1).

Figure 1: Distribution of carbapenem susceptibility tests among the 100 clinical isolates of *P.aeruginosa*.

Based on PCR result (Figure 2), 60 (60.0%) out of 100 clinical isolates of *Pseudomonas aeruginosa* were positive for *bla*OXA-48 resistance gene (Figure 3).

Figure 2: Amplified DNA under ultra violet light machine showing *bla* OXA-48 positive result. Lane 1, DNA leader 100 bp ; Lanes 2,3, 4, 5 negative samples. Land 6 was a positive sample (typical band size of 177 bp corresponding to the molecularsize of *bla* OXA-48 gene).

Figure 3: Frequency of blaOXA-48 resistance gene among the 100 *Pseudomonas aruginosa* clinical isolates.

Out of 81 carbapenem resistant strains 54(66.7%) were positive for *bla* Oxa-48 resistance gene, while among the 19 sensitive strains 6 (31.6%) were positive for blaOXA-48 gene (Table 2). There was a statistically significant association between carbapenem susceptibility and the frequency of *bla*OXA-48 gene with (*P-value* =0.006).

Table 2: Frequency of *bla* OXA-48 gene according to carbapenem (Meropenem, Imipenem) susceptibility testing

Carbapenem susceptibility test	OXA-48 gene		Total
	Present	Absent	
Resistance	54 (66.7%)	27 (33.3%)	81 (100.0%)
Sensitive	6 (31.6%)	13 (68.4%)	19 (100.0%)
Total	60 (60.0%)	40 (40.0%)	100 (100.0%)
<i>P-value</i>	0.006		

Table (3) showed that the frequency of blaOXA-48 gene among the resistant strains was most common among wound swabs 29 (53.7%) followed by urine 14 (25.9%) (*P value* > 0.05), similar, it was most frequent among wound swabs 5 (83.3%) followed by urine 1 (16.7%) among the sensitive

strains (P value > 0.05) (Table 3-4). There was a statistically insignificant association between the frequency of *bla*OXA-48 gene and the type of specimens.

Table 3: Frequency of carbapenemase *bla* OXA-48 gene among the carbapenem resistant strains of *P.aeruginosa* according to the type of specimens

Specimens	OXA-48 gene		Total
	Present	Absent	
Wound swab	29 (53.7%)	15 (55.6%)	44 (54.3%)
Urine	14 (25.9%)	7 (25.9%)	21 (25.9%)
Ear swab	2 (3.7%)	1 (3.7%)	3 (3.7%)
Sputum	5 (9.3%)	1 (3.7%)	6 (7.4%)
High vaginal swab	4 (7.4%)	3 (11.1%)	7 (8.6%)
Total	54 (100.0%)	27 (100.0%)	81 (100.0%)
<i>P-value</i>	0.903		

Discussion

Carbapenem resistance mediated by carbapenemases is an important issue in infection control programmes [23]. *Bla*OXA-48 represents the main enzyme among OXA β -lactamases isolated around the world [24].

In the present study it was found that among the total (100) clinical isolates, the most common isolates were from wound swab specimens, because *Pseudomonas aeruginosa* leading to cause of health care acquired infections most commonly associated with wound infections [25].

In the current study the frequency of *bla* OXA-48 resistance gene was 60% out of 100 *Pseudomonas aeruginosa* clinical isolates. Our result was higher than that study done in Sudan by Mohamed *et al.*, (2018) [26] it was found out of 67 *P. aeruginosa* clinical isolates 22.4% were positive for *bla* OXA-48 resistance gene by real time PCR, This may be due to differences in sample size.

Among (81) carbapenem resistant isolates 54 (66.7%) were positive for *bla*OXA-48 resistance gene (P value < 0.05). It was noted that the absence of *bla* OXA-48 resistance gene among the 27(33.3%) resistant strains may be due to impermeability, which arise via the loss of the Opr D porin, the up-regulation of active efflux pump system present in cytoplasmic membrane of the

bacteria and *bla* OXA-48 resistance gene encoded on mobile genetic elements, it has ability to transfer from one bacterium to another [27]. Or they may possess other type of carbapenemase enzymes rather than *bla* OXA-48 gene. While among the (19) carbapenem sensitive isolates, 6 (31.6%) were positive for *bla* OXA-48 resistance gene. The presence of resistance gene among the sensitive strains may indicate that there might be a hidden *bla* OXA-48 gene among them which cannot be diagnosed by phenotypic tests as mentioned in study done by Adam *et al.* (2018) [28].

The present study showed that there was a statistically insignificant association between the frequency of *bla*OXA-48 gene and the type of specimens, although there was a high frequency of *bla* OXA-48 resistance gene among wound swabs than other type of specimens. This may be due to the large sample size of wound swabs compared with other specimens, and *P.aeruginosa* was most commonly associated with wound infections.

Conclusion:

In the present work, the significant high frequency of *bla* Oxa-48 resistance gene among the resistance strains may indicate that it is a main source of initiating resistance among these strains, while its presence among carbapenem sensitive isolates suggesting the occurrence of silent gene, that encoded in a movable genetic elements (plasmid), therefore, it plays a key role in the transfer of horizontal resistance gene from one bacterium to another. Therefore prevention and control programs of carbapenem resistant should be performed to prevent the spread of carbapenemase producers, which includes appropriate use of antimicrobials and facility-level prevention strategies, as recommended by CDC (Centers for Disease Control and prevention).

Wound swabs were the predominant specimens harboring *bla* OXA-48 gene followed by urine samples.

References

1. **Chang HH, Cohen T, Grad YH, Hanage WPO, Brien TF, Lipsitch M** (2015) Origin and proliferation of multiple-drug resistance in bacterial pathogens. *Microbiology and Molecular Biology Review*, **79**(1):101-16.
2. **Zheng P, Renee R, Bernard RG, Tong-Jun L, Zhenyu C** (2019). Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnology advances*, **37**: 177-192.

3. **Estepa V, Rojo-Bezares B, Torres C., Saenz Y** (2014). Faecal carriage of *pseudomonas aeruginosa* in healthy humans; antimicrobial susceptibility and global genetic lineages. *Federation of European Microbiological Societies Microbiology Ecology* **89**(1): 15-9.
4. **Ciofu O, Tolker-Nielsen T, Jensen PO, Wang H, Hoiby N** (2015). Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. *Advanced Drug Deliv Rev*, **85**:7-23.
5. **Gomez-Zorrilla S, Camoez M, Tubau, F., Periche E, Cañizares R, Dominguez MA, et al.**,(2014). Antibiotic pressure is major risk factor for rectal colonization by multi drug-resistance *pseudomonas aeruginosa* in critically ill patients. *Antimicrobial agents Chemotherapy*, **58** (10) 63-70.
6. **Acharya M, Joshi PR, Thapa K** (2017) Detection of metallo-beta lactamases-encoding genes among clinical isolates of *pseudomonas aeruginosa* in a tertiary care hospital, Kathmandu, Nepal. *BMC Research Notes*, **10** (1): 718.
7. **Toval F, Guzman A, Madriz V** (2015) Predominance of carbapenem-resistant *pseudomonas aeruginosa* isolates carrying bla IMP and blaVIM metallo-Beta lactamase in a major hospital in Costa Rica. *Journal of Medical Microbiology*, **64**(1): 37-43.
8. **Huang S, Liu M, Lin C, Shi Z** (2014) Molecular surveillance and clinical outcomes of carbapenem-resistant *Escherichia coli* and *Klebsiella pneumonia* infection. *Journal of Microbiology, Immunology and Infection*, **47**(3):187-196.
9. **Sahuquillo-Arce JM, Hernández-Cabezas A, Yarad-Auad F, Ibáñez-Martínez E, Falomir-Salcedo P, Ruiz-Gaitán A** (2015) Carbapenemases: a worldwide threat to antimicrobial therapy. *World J Pharmacol*, **4**(1): 75–95.
10. **Poirel L, Marque S, Héritier C, Segonds C, Chabanon G, Nordmann P** (2005) . OXA-58, a novel class D (beta)-lactamase involved in resistance to carbapenems in *Acinetobacter baumannii*. *Antimicrobial Agents and Chemotherapy*, **49** (1): 202–208.
11. **Carrër A, Poirel L, Yilmaz M, Akan OA, Feriha C, Cuzon G, et al.**, (2010). Emerging spread of OXA-48-encoding plasmid from Turkey and beyond. *Antimicrob Agents and Chemother*, **54**: 1369–73.
12. **Florian P, Maurer; Claudio, C.; Chantal, Q.; Guido, V.; Bloemberg and Michael, H.**, (2015). Evaluation of Carbapenemase Screening and Confirmation Tests with

- Enterobacteriaceae* and Development of a Practical Diagnostic Algorithm. *Journal of Clinical. Microbiology*, **53**: 95–104.
13. **European Committee on Antimicrobial Susceptibility Testing** (2013) Guidelines for detection of resistance mechanisms and specific resistances of clinical and /or epidemiological importance .Version 1.0. *European committee on antimicrobial susceptibility testing*, Basel, Switzerland.
 14. **Dijk KV, Voets GM, Scharringa J, Voskuil S, Fluit AC, Rottier WC, Leverstein-Van Hall MA, Cohen Stuart, JWT** (2014) A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in *Enterobacteriaceae* using phenyl boronic acid, dipicolinic acid and temocillin. *Clin Microbiol Infect*, **20**: 345–349.
 15. **Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG** (2013) Evaluation of the Carba NP test for rapid detection of carbapenemase-producing *Enterobacteriaceae* and *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemother*, **57**: 4578-4580.
 16. **Laurent P, Anai S, Potron, Patrice N** (2012) OXA-48-like carbapenemases: the phantom menace. *Journal of Antimicrob Chemother*, **67**: 1597–1606.
 17. **Livermore DM, Woodford N** (2006). The β -lactamase threat in *Enterobacteriaceae*, *Pseudomonas* and *Acinetobacter*. *Trends in Microbiology*, **14**(9): 413–420
 18. **Carre'r A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P** (2008) Spread of OXA-48-positive carbapenem-resistant *Klebsiella pneumoniae* isolates in Istanbul, Turkey. *Antimicrobial. Agents and Chemotherapy*. 52:2950–2954.
 19. **Cuzon, G, Ouanich J, Gondret R, Naas T, Nordmann P** (2011). Outbreak of OXA-48-positive carbapenem-resistant *Klebsiella pneumoniae* isolates in France. *Antimicrob. Agents Chemother*, **55**(5): 2420-2423
 20. **Pasteran F, Tijet N, Melano RG, Corso A** (2015). Simplified protocol for carba NP test for enhanced detection of carbapenemase producers directly from bacterial cultures. *Journal of Clinical Microbiology*, **53** (12): 3908-3911.
 21. **Dahab RA, Alamin AM, Altayb HN** (2017). Phenotypic and genotypic detection of carbapenemase enzymes producing gram negative bacilli isolated from patients in Khartoum state. *F1000 Research* , **6**: 16-56.

22. **Monteiro J, Widen RH, Pignatari AC, Kubasek C, Silbert S** (2012). Rapid detection of carbapenemase genes by multiplex real time PCR. *Journal of Antimicrob Chemother*, **67** (4): 906-9.
23. **Peter S, Lacher A, Marschal M, Hölzl F, Buhl M, Autenrieth I, et al.,** (2014) . Evaluation of phenotypic detection methods for metallo- β -lactamases (MBLS) in clinical isolates of *Pseudomonas aeruginosa*. *European Journal of Clinical Microbiology & infectious Diseases*, **33**(7):33-41.
24. **Nordmann, P.; Naas, T. and Poirel, L.,** (2011) Global spread of carbapenemase producing Enterobacteriaceae . *Emerging Infectious Diseases*, **17** (10): 1791-1798.
25. **Yagoup MA, Taha. AA, Mubarak AK, Abdlla AE, Ournasseir ME, Abosalif KOA, et al.** (2018) Drugs-Resistant *Pseudomonas aeruginosa* Isolated from Various Clinical Specimens in Khartoum, Sudan. *P J M H S*, **2** 13(2): 441-444.
26. **Mohamed SER, Alobied A, Hussien WM, Saeed MI** (2018) blaOXA-48 Carbapenem Resistant *Pseudomonas aeruginosa* Clinical Isolates in Sudan. *Journal of Advances in Microbiology* 10 (4): 1-5.
27. **Murphy TA, Simm AM, Toleman MA, Jones RN, Walsh TR** (2003). Biochemical characterization of the acquired metallo- β -lactamase SPM-1 from *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* , **47** (2) : 582-7.
28. **Adam MA, Elhag WI** (2018). Prevalence of Metallo-beta lactamase Acquired Genes among Carbapene ms Susceptible and Resistant Gram Negative Clinical Isolates Using Multiplex PCR. *BMC infectious Diseases*, **18** (1): 668.

Figure 1: Distribution of carbapenem susceptibility tests among the 100 clinical isolates of *P. aeruginosa*

Figure 2: Amplified DNA under ultra violet light machine showing *bla* OXA-48 positive result. Lane 1, DNA ladder 100 bp ; Lanes 2,3, 4, 5 negative samples. Lane 6 was a positive sample (typical band size of 177 bp corresponding to the molecular size of *bla* OXA-48 gene).

Figure 3: Frequency of blaOXA-48 resistance gene among the 100 *Pseudomonas aruginosa* clinical isolates.